Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02768467
Other study ID # 16-00669
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date April 10, 2017
Est. completion date April 9, 2018

Study information

Verified date June 2019
Source NYU Langone Health
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Prior studies have been performed to understand the optimal way to minimize the morbidity rate of buccal mucosa. While some studies have reported primary closure to be inferior to healing by secondary intention, this appears to be true for large defects greater than 2 cm in width. For small defects for which the wound can be closed without tension, the most recent study has shown improved pain outcomes in the immediate post-operative setting, although no difference is seen long term whether or not the wound was primarily closed. However, for larger defects, standard practice is to allow delayed healing by secondary intention.

The use of Alloderm graft placement for donor site coverage was first described in Armenakas' group. Alloderm is an acellular dermal lattice from human allograft skin. The only study to report the use of Alloderm failed to find a significant improvement in patient outcomes; however, very small defects were included in this study and the control group underwent primary closure, which has been shown to be inferior for large defects. Importantly, no increase in post-operative pain was noted, although there was some increased swelling reported. From experience, patients with moderate and large (>2 cm width) defects following buccal mucosa harvest benefit from Alloderm placement with decreased post-operative pain, more rapid resumption of normal diet and mouth function with no associated increase in morbidity of the procedure. This study aims to determine whether this is a reliable improvement in technique.

This study will clarify how the cheek heals after the buccal mucosa is removed during reconstructive surgery. Subjects will be randomized to either receive tissue collagen matrix or no stitches after the surgery. Subjects will be evaluated up to six months to determine if the outcomes of the tissue matrix graft are better for the subject.


Recruitment information / eligibility

Status Completed
Enrollment 50
Est. completion date April 9, 2018
Est. primary completion date April 9, 2018
Accepts healthy volunteers No
Gender Male
Age group 18 Years and older
Eligibility Inclusion Criteria:

- >18 years of age

- Male

- Patients with clinically necessary buccal mucosal graft >2 cm

- Patients who are able to present for pre-operative and post-operative evaluations

- Patients who are able to comprehend and read English

Exclusion Criteria:

- History of oral cancer

- Severe cognitive impairments

- Unwilling or unable to follow procedures in protocol

- Contraindicated to participate for any reason

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Tissue Matrix Graft Placement
Subject will receive a covering for the wound post buccal mucosa removal.
No Stitches
Subject will not receive stitches post buccal mucosa removal.

Locations

Country Name City State
United States New York University Langone Medical Center New York New York

Sponsors (1)

Lead Sponsor Collaborator
NYU Langone Health

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Pain Level Measured by the Visual Analog Scale Six months
Secondary Time to Normal Eating This is measured by time. Six Months
Secondary Presence of Swelling This is measured by time Six Months
Secondary Mouth mobility This is measured by time Six Months
Secondary Presence of Paresthesia This is measured by time Six Months